Algorae Pharmaceuticals (ASX: 1AI) has completed the prediction-generation phase of a multi-anchor drug combination program using AlgoraeOS v2 (AOS2) to produce in silico synergy predictions across 18 candidates.
The program—which follows the generation of synergy predictions for cannabidiol (CBD) achieved during the company’s first single-anchor campaign at the Peter MacCallum Cancer Centre in Victoria—will involve new anchors that span a diverse range of therapeutic areas and mechanisms of action.
It will evaluate 18 anchor drugs in combination with thousands of approved and investigational compounds across a panel of human cell lines, representing over nine million potential drug-drug-cell line combinations, leveraging the scale and efficiency of the AI-powered AOS2 platform to provide Algorae with a more diverse pipeline of predicted combination opportunities.
Each prediction in the dataset will include the four recognised synergy metrics (namely ZIP, Bliss, HAS, and Loewe) alongside confidence-weighted measures of predictive uncertainty to enable rigorous, risk-aware prioritisation across the full prediction set and underpin the company’s structured approach to candidate selection.
Structured Analysis Underway
Algorae has commenced a structured analysis of the multi-anchor prediction set, applying prioritisation thresholds informed by the methodology applied to the original CBD prediction set.
Initial filtering has identified more than 478,000 individual synergy predictions passing preliminary synergy and uncertainty thresholds, along with more than 6,000 drug combinations demonstrating predicted synergy across multiple cell lines, indicating greater biological robustness.
With the larger scale and greater diversity of the multi-anchor program, the next phase will incorporate anchor-specific considerations and apply additional filters.
These are intended to reflect the predicted strength and consistency of synergy, biological robustness across cell lines, the novelty of each combination relative to existing empirical data, and commercial and intellectual property relevance
Platform Demonstrating Value
Algorae chief scientific officer Dr James McKenna said the multi-anchor program demonstrated the value of the company’s predictive drug platform.
“This program provides a compelling demonstration of the in silico predictive capability of AOS2 through the rapid generation of large-scale predictions across approved and investigational drugs with diverse mechanisms of action,” he said.
“In doing so, it has dramatically expanded our pool of candidate drug combinations for further evaluation, while reducing reliance on traditional, resource-intensive screening methods.”
In parallel with its AI drug discovery activities, the company continues to progress its commercial pharmaceutical pipeline with additional products and agreements.